SICOT 2025: Denosumab and Type 2 Diabetes Risk in Osteoporotic Patients
Potential Role Of Denosumab In Reducing Type 2 Diabetes Risk And Improving Glycemic Control In Osteoporotic Patients
Nine studies with 172,385 osteoporotic patients were included in this systematic review and meta-analysis comparing denosumab with placebo or other osteoporosis treatments. Pooled outcomes of interest included incidence of type 2 diabetes mellitus (T2DM), fasting blood sugar (FBS), HbA1c, and HOMA-IR. Denosumab was associated with a 26% reduction in T2DM incidence and modest improvements in FBS, though no significant changes were observed in HbA1c or HOMA-IR. Overall, denosumab may provide metabolic benefits beyond bone health, but its effects on long-term glycemic control remain uncertain.
Unlock the Full ACE Report
You have access to 4 more FREE articles this month.
Click below to unlock and view this ACE Reports
Unlock Now
Critical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidencecontent for as little as $1.99 per week.
Already have an account? Log in
0 of 4 monthly FREE articles unlocked
